For Health Professionals

Clinical Research

Sponsorships & Collaborations

Past Studies

Our teams have undertaken a number of sponsored trials. Here are some examples of past studies.

PARADIGM-HF Led by Dr Ong Hean Yee (Cardiology)

PARADIGM-HF was an industry-sponsored clinical trial conducted in KTPH between 2009 and 2013. The trial tested a new heart failure medication that is now made available in Singapore after the clinical trial. With 29.9%* of deaths caused by Cardiovascular Diseases in 2014, the new medication is set to benefit many heart disease patients in the near future.

Spearheaded by Dr Ong Hean Yee in KTPH, the results of the trial which was published in 2014’s New England Journal of Medicine, demonstrated that patients who were given the new LCZ696 medication had a 20% and 21% reduced risk of death and hospitalization for heart failure respectively. The trial stopped 10 months earlier than intended because preliminary data showed overwhelming benefits the new medication could provide. Now available in the market, this is the first novel class of medication that is able to improve on mortality in heart failure since 1999.

KTPH’s participation in this trial was featured in numerous local newspapers such as The Straits Times, Berita Harian, The New Paper and My Paper in March and April 2016.

News Link: http://www.straitstimes.com/singapore/health/spore-approves-new-heart-failure-drug

EMPA-REG OUTCOME Led by A/Prof Sum Chee Fang (Diabetes Centre)

In 2012, KTPH participated in EMPA-REG OUTCOME – an industry-sponsored trial conducted in 42 countries globally and involved a total of 7,028 diabetes patients between 2010 and 2013. Empagliflozin, the drug that was tested, was later described by The Straits Times to be ‘ a game-changer in the treatment of diabetes.

Results from the trial showed that type 2 diabetes patients had a lower rate of cardiovascular outcome when empagliflozin was prescribed in addition to the standard diabetes medication. The study was published in the New England Journal of Medicine. With strong evidence that empagliflozin can help with reducing cardiovascular risk, the new drug was submitted to the Health Sciences Authority (HAS) for registration, and has been approved for use in Singapore since December 2014.

News Link: http://www.straitstimes.com/singapore/new-drug-may-lower-heart-risk-in-diabetics

ROCKET-AF (Atrial Fibrillation) & VTE Study Led by Dr Ong Hean Yee (Cardiology)

Rivaroxaban has been used in Singapore to prevent blood clots from forming in the veins of adults undergoing total hip or knee replacement surgery. In December 2013, the drug was given the approval to be used as an oral blood thinner by the Health Sciences Authority (HSA).

The ROCKET-AF clinical trial was conducted to investigate how effective Rivaroxaban is in reducing the risk of ischemic stroke in patients with atrial fibrillation as compared to conventional anticoagulation medication (warfarin). The trial recruited and followed-up a total of 14,264 patients with atrial fibrillation globally between 2006 and 2010, of which 44 patients were from Singapore. The data, published in the New England Journal of Medicine in 2011, concluded that Rivaroxaban worked as well as warfarin in preventing stroke or systemic embolism. In conjunction with ROCKET-AF, Dr Ong also led a team to investigate the incidences of venous thromboembolism (VTE), i.e. blood clots that form in veins, and the prescription of thromboprophylaxis amongst Asians. The cross-sectional study collected data from 1,103 KTPH patients who had undergone major orthopaedic or abdominal 2.1%. The study also found that patients over 75 years old are at higher risk of VTE. The findings have allowed KTPH to manage the risk of VTE, and to prevent the development of this fatal condition on our post-operative patients. The outcome of the VTE study was reported in Shin Min Daily News, The New Paper and Lianhe Wanbao in April 2014, as well as in The Straits Times in June 2014.

News Link: http://health.asiaone.com/health/health-news/singapore-study-debunks-blood-clot-myth

For information on setting new clinical trials,
please contact: ktph.cru.admin@ktph.com.sg & yee.grace.pc@ktph.com.sg

Our Research Collaborators

Saw Swee Hock School of Public Health (SSHSPH)

With our comprehensive lab facility and excellent research teams, we have had multiple fruitful collaborations with international leading scientists and institutions.

  • Prospectively follow up individuals with diabetes recruited from our Diabetes Centre (collaboration with SSHSPH and NUS)
  • A multi-institutional collaboration with SSHSPH involved Tan Tock Seng Hospital, Genome Institute of Singapore, B.R.A.H.M.S Biotechnology centre (Germany) and Singapore General Hospital. It studied the association between pathway-related candidate genes with “intermediate phenotype” and diabetic nephropathy using customised microarray of 1,536 SNPS.

Genome Institute of Singapore (GIS)

Our Infection Control team has ongoing collaborations with GIS which includes environmental surveillance of Methicillin-resistant Staphylococcus aureus (MRSA) and genomic exploration of the nasal microbiome in S. aureus carrier and non-carriers.

Our common interest in the genetics of diabetic nephropathy also led to a fruitful collaboration with GIS.

Future collaborations include genetics of healthy aging.

NHG Institutions (TTSH, NHGPs)

Our research team specialising in diabetes and urology is intrigued by the genetics implications in diabetes nephropathy. With this special interest in mind, we have teamed up with Tan Tock Seng Hospital (TTSH).

We also worked with NUS, NHG Polyclinics and TTSH to study how to better manage diabetes in patients under the care of specialist centres.

National University Health System (NUHS)

A collaboration was also made with Biopolis and NUS to study the molecular epidemiology of nephropathy secondary to type 2 diabetes.

Dr Subramaniam Tavintharan is working with NUS on the mechanisms of simvastatin-induced hepotoxicity to study hepatic gene expression profiles to explain the pathogensis of hepatopathy.

Dr Subramniam Tavintharan is also working closely with Saw Swee Hock School of Public Health, NUS, on untargeted metabolomics to understand how certain metabolite signatures can distiguish patients of different glucose tolerance.

We have also had continuous collaboration with the Department of Biochemistry in NUS to study the genome wide transcriptomic study on HepG2 cells treated – with NUS Dept of Biochemistry

Another collaboration with the Department of Biochemistry, NUS involves miRNA profiling of subjects with and without metabolic disorders.

Nanyang Polytechnic

We collaborated with the School of Chemical and Life Science, Nanyang Polytechnic to identify novel urinary biomarkers in non-albuminuric diabetic nephropathy subjects.

Singhealth Services (SGH, SERI)

Dr Lim Su Chi has had a multi-institutional collaboration with SGH, SERI and NUS to study the metabolic syndrome and microangiopathies in Asians.

Another collaboration sees Dr Lim Ling Choo working with NUS, NUH and SGH on the study Detection of RET/PTC expression and its role as a molecular and prognostic marker in our local patients with papillary thyroid carcinoma.

Singapore Institute of Clinical Science, A*STAR

Our bariatric surgery and adipocytes biology research attracted strong interest from leading international scientists from SICS, like Prof Sir Peter Gluckman, Prof Judith Swain and Dr Michael Meaney.

We will be collaborating with SICS on a translational medicine approach to identify genomic and epigenomic causes of Type 2 Diabetes Mellitus.

We are also part of the Singapore Consortium of Cohort Studies (SCCS) which is a national effort to develop a large multi-ethnic population-based cohort study that would facilitate research into the complex gene-environment interactions in diseases such as diabetes, cardiovascular diseases and cancers. Specifically, we are involved in examining the genetic and environmental factors that are important in the development of diabetic complications in diabetic patients.